DexCom is a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for use by people with diabetes and by healthcare providers. Co.'s products include: DecCom G6®, which is designed to allow Co.'s transmitter to run an algorithm to generate a glucose value; Dexcom G7®, which is designed for all people with diabetes ages two years and older, giving access to a diabetes management solution; DexCom Share®, which is a remote monitoring system, provided for use with any existing Dexcom system; Dexcom Real-Time API, which expands connectivity and interoperability of the Dexcom CGM digital ecosystem; and Dexcom ONE®.
When researching a stock like DexCom, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from DXCM Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for DXCM stock — the real life supply and demand for the stock over time — and examines that data in different ways. |
43.19
Free DXCM Email Alerts:
Video: Technical Analysis